Stock listing

Shanghai:688315 Novogene Co., Ltd. (诺禾致源) 股价

Follow Novogene Co., Ltd. into a list and get an email when it puts out news.

Share price · SSE:688315

¥15.20 CNY -1.76 (-10.4%)

Close on Nov 20, 2026

Past year +9.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥15.08 – ¥15.77 CNYNov 20, 2026
Volume
10.42M sharesNov 20, 2026
Market cap
¥6.33B CNYAt the close on Nov 20, 2026 · price × 416.2M shares outstanding
52-week range
¥11.46 – ¥23.43 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥354.2M CNYMedian day 19.15M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Novogene Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688315 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥15.20-1.76-10.4%¥15.68¥15.77¥15.0810,423,267
¥16.96-0.40-2.3%¥17.64¥17.64¥16.4714,038,607
¥17.36-0.65-3.6%¥17.74¥18.20¥17.2013,260,621
¥18.01+0.13+0.7%¥17.52¥18.98¥16.7420,672,782
¥17.88-1.73-8.8%¥19.56¥19.86¥17.8119,112,784
¥19.61-0.71-3.5%¥20.10¥20.88¥19.6117,414,857
¥20.32+0.46+2.3%¥20.17¥20.39¥19.3816,253,712
¥19.86+0.74+3.9%¥19.70¥20.20¥19.1619,563,202
¥19.12+0.54+2.9%¥18.70¥20.15¥18.6316,161,780
¥18.58-0.67-3.5%¥18.46¥19.48¥18.1619,178,239
¥19.25+2.00+11.6%¥17.14¥19.44¥17.0329,664,195
¥17.25+0.79+4.8%¥16.33¥17.40¥15.3828,150,238
¥16.46-2.37-12.6%¥18.70¥18.70¥16.4525,077,851
¥18.83+0.52+2.8%¥18.33¥19.12¥17.3221,484,648
¥18.31-0.94-4.9%¥18.98¥20.35¥17.5129,352,442
¥19.25-0.64-3.2%¥19.69¥20.60¥19.2126,447,938
¥19.89+3.05+18.1%¥16.84¥20.21¥16.8432,672,232
¥16.84-1.21-6.7%¥18.14¥18.23¥16.7814,630,920
¥18.05-1.30-6.7%¥19.01¥19.10¥17.5521,043,763
¥19.35+1.16+6.4%¥17.78¥19.47¥16.9022,445,235
¥18.19-1.45-7.4%¥19.89¥19.92¥18.1423,224,304
¥19.64+1.41+7.7%¥19.30¥21.19¥18.9133,300,172
¥18.23+0.91+5.3%¥17.08¥18.66¥16.7019,030,713
¥17.32-0.51-2.9%¥17.48¥18.45¥16.5422,374,737
¥17.83-1.33-6.9%¥19.00¥20.77¥17.4827,112,243
¥19.16-0.47-2.4%¥18.20¥21.10¥18.2023,094,888
¥19.63-0.92-4.5%¥20.14¥20.59¥19.5618,083,443
¥20.55-1.46-6.6%¥21.13¥21.60¥19.9527,407,211
¥22.01+0.28+1.3%¥21.60¥23.43¥20.7839,417,070
¥21.73+2.80+14.8%¥18.91¥22.55¥17.4137,935,026
¥18.93-0.84-4.2%¥20.14¥20.47¥18.5927,194,790
¥19.77+0.87+4.6%¥18.69¥21.17¥18.5730,215,584
¥18.90-1.16-5.8%¥19.84¥20.05¥18.6127,245,141
¥20.06-0.34-1.7%¥20.99¥21.40¥19.3929,138,815
¥20.40+1.01+5.2%¥19.23¥21.49¥18.7035,993,118
¥19.39+0.37+1.9%¥18.98¥19.67¥18.4127,589,940
¥19.02+0.84+4.6%¥19.33¥20.18¥18.4449,413,691
¥18.18+3.03+20.0%¥16.59¥18.18¥16.4217,898,053
¥15.15+1.18+8.4%¥14.14¥16.04¥14.1316,615,933
¥13.97+0.21+1.5%¥13.69¥14.48¥13.507,696,904
¥13.76+0.47+3.5%¥13.35¥13.87¥13.184,404,522
¥13.29-0.28-2.1%¥13.39¥13.66¥13.283,569,180
¥13.57+0.76+5.9%¥12.81¥13.61¥12.706,532,575
¥12.81-0.54-4.0%¥13.29¥13.29¥12.694,899,243
¥13.35-0.47-3.4%¥13.77¥13.78¥13.304,616,195
¥13.82-0.19-1.4%¥13.88¥13.94¥13.684,325,839
¥14.01+0.21+1.5%¥13.80¥14.10¥13.565,220,406
¥13.80-0.15-1.1%¥13.95¥14.00¥13.674,512,092
¥13.95-0.18-1.3%¥14.29¥14.45¥13.895,630,873
¥14.13-0.21-1.5%¥14.20¥14.56¥14.074,608,277
¥14.34-0.34-2.3%¥14.73¥14.74¥14.255,454,783
¥14.68-0.10-0.7%¥14.78¥14.98¥14.565,818,040
¥14.78-0.75-4.8%¥15.18¥15.26¥14.677,172,150
¥15.53-0.51-3.2%¥15.81¥16.13¥15.399,281,856
¥16.04+0.22+1.4%¥15.70¥16.73¥15.4112,822,554
¥15.82-0.25-1.6%¥16.50¥16.50¥15.6511,625,147
¥16.07-0.86-5.1%¥17.01¥17.01¥15.7617,487,541
¥16.93+0.98+6.1%¥15.95¥17.09¥15.5122,325,603
¥15.95-1.15-6.7%¥16.47¥17.49¥15.7530,386,001
¥17.10+2.23+15.0%¥16.40¥17.84¥16.2029,004,320
Ticker
Shanghai:688315
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All Novogene Co., Ltd. news

Novogene Co., Ltd. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
11 in the last 12 months · 43 in all · newest Nov 6, 2026 · oldest 2024

Valuation

P/E 43.1× against a median of 18.8×: 5th lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥4.57B CNY
P/E
43.1×
EV/sales
2.0×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.3×
Gross margin
43.1%
Operating margin
6.9%
Net margin
6.4%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Novogene Co., Ltd. Class A · SSE:688315US$949.6MUS$685.6M43.1×2.0×n/a2.3×6.4%0.0×n/a
Beijing Strong Biotechnologies Inc Class A · SZSE:300406US$1.05BUS$1.13B28.0×5.5×n/a1.9×18.2%0.3×n/a
Freenome, Inc. · NASDAQ:FRNMUS$1.04BUS$863.3M9.5×n/an/a2.2×n/a0.0×n/a
Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVIUS$1.04BUS$1.11Bn/a5.2×n/a5.3×−30.8%0.8×1.56
Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137US$1.02BUS$909.1Mn/a38.0×n/a3.4×−60.8%0.0×n/a
Castle Biosciences, Inc. · NASDAQ:CSTLUS$1.01BUS$745.1Mn/a2.0×n/a2.1×−6.1%0.0×1.00
Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482US$1.01BUS$785.0Mn/a2.7×n/a1.2×−3.2%0.0×n/a
St Pharm Co., Ltd. · KRX:237690US$992.8MUS$866.1M17.4×3.0×11.1×2.1×19.9%0.0×n/a
Daan Gene Co., Ltd. Class A · SZSE:002030US$990.1MUS$810.9Mn/a7.0×n/a0.9×−95.7%0.0×n/a
Amoy Diagnostics Co., Ltd. Class A · SZSE:300685US$967.3MUS$801.3M18.8×4.4×n/a3.3×28.5%0.1×n/a
Innovita Biological Technology Co., Ltd. Class A · SSE:688253US$925.5MUS$658.4M113×14.2×n/a3.0×17.7%0.0×n/a
Median of the othersUS$1.01BUS$837.1M18.8×5.2×11.1×2.1×−3.2%0.0×1.28

Forecasts

Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
19.53 CNY · Analysts' mean
EPS, year to Dec 2026
0.52 · 1 analyst
Revenue, year to Dec 2026
2.4B · 3 analysts

Events

QuarterResultsShare move
Q2 2023Jul 31, 2023 · Before open+0.4%
Q1 2023Apr 12, 2023 · Before open+4.2%
Q3 2022Oct 24, 2022 · Before open−2.3%
Q2 2022Aug 10, 2022 · After close+7.5%
Q1 2022Apr 26, 2022 · Before open−3.7%
Q4 2021Feb 24, 2022 · After close+9.4%
Quarter to Sep 30, 2021Oct 25, 2021 · Before open+4.7%
Quarter to Jun 30, 2021Aug 13, 2021 · After close−11.0%
Quarter to Mar 31, 2021Apr 27, 2021 · Before open+20.0%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.21B2.11B2.00B1.93B1.87B1.49B1.53B1.05B739.3M458.5M
Cost of revenue1.27B1.19B1.15B1.08B1.07B972.4M934.0M601.7M422.9M238.4M
Gross profit939.8M917.6M852.4M849.1M793.9M517.6M600.8M451.8M316.5M220.1M
Research and development159.9M131.7M124.2M125.6M145.3M112.3M125.7M79.4M50.4M30.5M
Selling, general and administrative175.3M156.1M176.1M171.0M148.1M121.7M116.8M94.1M73.0M45.1M
Operating income193.5M234.0M214.9M212.5M246.5M36.1M119.3M112.9M88.9M44.3M
Depreciation and amortization149.1M159.2M152.5M132.1M131.0M105.7M88.8M81.9M48.0M21.3M
EBITDA342.6M393.1M367.3M344.5M377.5M141.7M208.1M194.8M136.9M65.6M
Interest expense1.84M2.92M3.54M3.91M4.47M11.9M3.64M1.02M2.63M1.11M
Income before tax192.9M224.7M212.6M208.6M246.5M35.5M119.2M112.9M88.9M49.6M
Income tax20.9M29.4M27.0M17.6M1.09M4.78M15.0M7.81M10.5M
Net income166.1M196.8M178.1M177.2M225.2M36.5M114.3M97.1M80.5M39.1M
Earnings per share, basic0.410.480.440.440.580.100.320.270.220.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents481.5M387.4M704.7M851.3M897.8M460.0M316.1M188.6M158.4M253.0M
Short-term investments1.29B1.25B826.9M191.1M166.2M30.0M52.0M
Receivables600.0M610.5M576.2M615.6M537.2M322.4M380.1M190.9M100.9M49.1M
Inventory294.7M163.7M181.5M197.1M230.6M201.6M197.8M146.1M140.8M87.5M
Current assets2.92B2.54B2.52B2.02B1.91B1.20B1.12B681.1M704.6M1.02B
Total assets3.94B3.64B3.59B3.05B2.86B2.02B1.97B1.47B1.35B1.23B
Accounts payable250.7M179.0M159.0M131.7M238.7M158.1M194.4M58.4M29.4M21.4M
Current liabilities1.21B1.10B1.09B1.03B1.02B897.5M872.9M487.0M472.6M416.5M
Total debt13.8M17.8M49.3M44.8M71.3M182.4M52.1M94.9M
Total liabilities1.26B1.12B1.12B1.07B1.06B903.9M883.2M499.2M487.9M433.6M
Shareholders' equity2.65B2.49B2.46B1.96B1.79B1.12B1.08B967.7M863.1M792.5M
Shares outstanding405.2M410.0M404.7M402.8M386.8M365.4M357.1M359.6M365.9M115.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations217.0M385.5M334.2M303.9M293.5M342.1M85.4M151.4M54.8M95.4M
Capital spending-104.2M-182.6M-116.7M-217.2M-112.0M-92.1M-172.6M-81.1M-496.9M-127.8M
Free cash flow112.7M203.0M217.5M86.7M181.5M250.0M-87.2M70.3M-442.2M-32.4M
Cash from investing-514.0M-784.6M-349.1M-191.8M-73.9M-139.6M-19.4M-106.0M-507.2M
Cash from financing-179.8M289.7M-44.8M358.8M-119.2M179.7M-51.4M-315.5K503.4M
Dividends paid-20.3M-19.4M-19.5M-24.3M-2.48M-9.27M-2.33M-557.2K-1.85M-3.37M
Share buybacks-144.2M
Change in cash93.8M-309.9M-135.1M-64.2M442.8M134.3M126.8M89.4M-55.3M92.5M

Open Financials

Filings

FilingDateTypeFiled with
(688315)"NOVOGENE CO., LTD."Voluntary AnnouncementNov 6, 2026Legal or regulatory actionShanghai Stock Exchange
(688315)"NOVOGENE CO., LTD."Announcement on Convening the Q3 2026 Performance BriefingOct 29, 2026Meeting noticeShanghai Stock Exchange
(688315)"NOVOGENE CO., LTD."Report for Q3 2026Oct 29, 2026Other filingsShanghai Stock Exchange
"NOVOGENE CO., LTD."Announcement on Abnormal Fluctuations in Stock TradingSep 22, 2026Other filingsShanghai Stock Exchange
"NOVOGENE CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Sep 10, 2026Meeting outcomeShanghai Stock Exchange
"NOVOGENE CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 25, 2026ResultsShanghai Stock Exchange
Voluntary AnnouncementJun 9, 2026Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2025Jun 2, 2026DividendShanghai Stock Exchange
Announcement on Resolutions of the 2025 Annual General MeetingMay 8, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Revising and Formulating Some Corporate Governance SystemsApr 14, 2026Other filingsShanghai Stock Exchange
All 42 filings
FilingDateTypeFiled with
Announcement on Preliminary Earnings Estimate for 2025Feb 26, 2026ResultsShanghai Stock Exchange
Announcement on Making Provisions for Asset Impairment for the First Three Quarters of 2025Oct 23, 2025Other filingsShanghai Stock Exchange
Resolutions of the 1st Extraordinary General Meeting in 2025Sep 1, 2025Meeting noticeShanghai Stock Exchange
2025 Semi-annual ReportAug 14, 2025Interim reportShanghai Stock Exchange
Announcement on Result of Shareholding Reduction by ShareholderJul 15, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution for 2024Jun 3, 2025DividendShanghai Stock Exchange
Announcement on Resolution of the 1st Meeting of the 4th Board of SupervisorsMay 7, 2025Other filingsShanghai Stock Exchange
Announcement on Electing Employee Representative Supervisor of the 4th Board of SupervisorsApr 28, 2025Other filingsShanghai Stock Exchange
2024 Annual ReportApr 14, 2025Annual reportShanghai Stock Exchange
Announcement on Resolution of the 19th Meeting of the 3rd Board of SupervisorsApr 11, 2025Other filingsShanghai Stock Exchange
Announcement on Resolution of the 18th Meeting of the 3rd Board of SupervisorsMar 21, 2025Other filingsShanghai Stock Exchange
Announcement on Plan of Shareholding Reduction by ShareholdersMar 19, 2025Other filingsShanghai Stock Exchange
Announcement on Preliminary Earnings Estimate for 2024Feb 26, 2025Other filingsShanghai Stock Exchange
Announcement on Abnormal Fluctuations in Stock TradingFeb 17, 2025Other filingsShanghai Stock Exchange
Announcement on the Results of Repurchasing Shares through Call AuctionFeb 5, 2025Other filingsShanghai Stock Exchange
Announcement on Changes in Audit Engagement Partner, Signatory Certified Public Accountant, and Quality Control ReviewerJan 14, 2025Other filingsShanghai Stock Exchange
Announcement on Progress in Repurchasing Shares through Call AuctionJan 2, 2025Other filingsShanghai Stock Exchange
Announcement on Convening the Q3 2024 Performance BriefingNov 15, 2024Other filingsShanghai Stock Exchange
Report for Q3 2024Oct 24, 2024Other filingsShanghai Stock Exchange
Announcement on Results of Shareholding Reduction by ShareholdersSep 29, 2024Other filingsShanghai Stock Exchange
Announcement on Resolution of the 16th Meeting of the 3rd Board of SupervisorsAug 21, 2024Other filingsShanghai Stock Exchange
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares by 1%Aug 15, 2024Other filingsShanghai Stock Exchange
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2024Aug 14, 2024Other filingsShanghai Stock Exchange
Announcement of Novogene Co., Ltd. on the Progress in Repurchasing Shares through AuctionJul 1, 2024Other filingsShanghai Stock Exchange
Announcement on Re-signing Agreement on Supervision over Raised Funds among Four Parties after Changing Investment Project Financed by Raised FundsJun 17, 2024Other filingsShanghai Stock Exchange
Announcement on Proportion of Shares Repurchased through Auction Reaching 1% of Total Share Capital and Progress in RepurchaseJun 5, 2024Other filingsShanghai Stock Exchange
Announcement on Progress in Repurchasing Shares through AuctionJun 3, 2024Other filingsShanghai Stock Exchange
Announcement on Implementation of Dividend Distribution of 2023May 24, 2024DividendShanghai Stock Exchange
Announcement on Adjusting Distribution Ratio per Share in Profit Distribution Plan of 2023May 13, 2024Other filingsShanghai Stock Exchange
Announcement on Resolutions of 2023 Annual General MeetingMay 6, 2024Meeting noticeShanghai Stock Exchange
Announcement on Circulation of Restricted Shares Issued to Specific ObjectsApr 16, 2024Other filingsShanghai Stock Exchange
Announcement on Estimated Daily Related Transactions in 2024Apr 12, 2024Other filingsShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from Novogene Co., Ltd. Class A’s releases

Common shares
416,200,000
Fully diluted
416,200,000

Fully diluted

LineShares
Common shares416,200,000

Share count over time

CountShares
Nov 22, 2026416,200,000

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Voya Multi-Manager International Small Cap Fund63,932US$120KNewJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF44,728US$82,432No changeJun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF2,436US$4,489No changeJun 30, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Novogene Co., Ltd.